Pharma Times -- Orexo has linked up with Johnson & Johnson in a research and licensing deal that could be worth around $600 million to the Swedish drugmaker. The agreement gives J&J units Ortho-McNeil-Janssen Pharmaceuticals and Janssen Pharmaceutica licenses to two of Orexo’s advanced preclinical programmes focusing on discovering and developing small-molecule treatments for asthma, chronic obstructive pulmonary disease and other inflammatory diseases. J&J will add a third programme to the alliance based on an undisclosed target.
